Latest Breaking News On - Therapeutic head - Page 1 : comparemela.com

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Katie kennedyAmit sharmaAshleyr robinsonJaclyn jaffeExchange commissionSecurities exchangeCheckpoint therapeutics incCompany contactClinical developmentFortress biotech incDana farber cancer instituteLifesci advisorsDrug administrationTherapeutics reports first quarterRecent corporateChief executive officer

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively.NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Compan.

United statesScott plevyDineshv patelCorey davisProtagonist therapeutics incNetwork of companiesExchange commissionTakeda pharmaceuticals co ltdProtagonist therapeuticsNew england journalPsoriasis areaSeverity indexGlobal assessmentPatient reported outcomesPsoriasis symptomsSigns diary

New England Journal of Medicine Publishes Efficacy and Safety Data

New England Journal of Medicine Publishes Efficacy and Safety Data .

United statesScott plevyDineshv patelNews networkProtagonist therapeutics incProtagonist therapeuticsNew england journalPsoriasis areaSeverity indexGlobal assessmentPatient reported outcomesPsoriasis symptomsSigns diaryDermatology life quality indexExecutive vice presidentTherapeutic head

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDineshv patelCorey davisScott plevyProtagonist therapeutics incTakeda pharmaceuticals co ltdNetwork of companiesExchange commissionProtagonist therapeuticsNew england journalPsoriasis areaSeverity indexGlobal assessmentPatient reported outcomesPsoriasis symptomsSigns diary

Protagonist Therapeutics (PTGX) Reports Publication of Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113

Protagonist Therapeutics (PTGX) Reports Publication of Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDineshv patelScott plevyProtagonist therapeutics incProtagonist therapeuticsNew england journalPsoriasis areaSeverity indexGlobal assessmentPatient reported outcomesPsoriasis symptomsSigns diaryDermatology life quality indexExecutive vice presidentTherapeutic head